Focus: GSK is a London-based multinational pharmaceutical company with 70,000 employees specializing in small molecules, vaccines, and biologics across vaccines, infectious disease, HIV/AIDS, oncology, and immunology. A public company founded in 2001, it competes among the world's largest integrated pharma firms.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Hot — 694 jobs added in 30d
Net +29 (694 new, 665 removed). Aggressive expansion phase.
GSK offers stable, large-scale pharma experience and a diversified pipeline, but faces imminent patent cliffs and ongoing layoffs—best for risk-tolerant candidates seeking big-company infrastructure without near-term growth tailwinds.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for GSK
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from GSK's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Represents 44% of revenue; loss of exclusivity in 2031 creates major cliff risk.
Second respiratory franchise losing patent protection on same date as TRELEGY.
Part of ELLIPTA platform facing LOE in 2030–2031 window.
First major patent expiration (Dec 2027); earliest cliff catalyst.
Legacy respiratory product; LOE date unclear but approaching exclusivity loss.
Earliest LOE among top 10 products; near-term revenue erosion expected.
181 discontinued, 48 duplicate formulations not shown
+18 more products with revenue data
8-K Filing: Cerebras Systems Inc. (CBRS) (CIK 0002021728) — EX-99.1
EX-99.1
8-K Filing: Aligos Therapeutics, Inc. (ALGS) (CIK 0001799448) — PRESS RELEASE
PRESS RELEASE
8-K Filing: Vaxcyte, Inc. (PCVX) (CIK 0001649094) — EX-99.1
EX-99.1
8-K Filing: Bicara Therapeutics Inc. (BCAX) (CIK 0002023658) — EX-99.1
EX-99.1
Stocks To Buy: Check Kush Bohra's Top Picks Of The Day | July 23, 2026 - NDTV Profit
Stocks To Buy: Check Kush Bohra's Top Picks Of The Day | July 23, 2026 NDTV Profit
GSK stock trades steadily as vaccines and specialty medicines support earnings - Ad-hoc-news.de
GSK stock trades steadily as vaccines and specialty medicines support earnings Ad-hoc-news.de
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Active restructuring underway; expect continued headcount rationalization and functional consolidation through 2027 as patent cliffs approach.
Recent peer-reviewed publications with author affiliations at this company
+36 more products
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo